Dow Jones Top Company Headlines at 1 AM ET: Saks Prepares for Bankruptcy After Missing Debt Payment | Baidu's ...

Dow Jones01-02

Saks Prepares for Bankruptcy After Missing Debt Payment

The owner of Saks Fifth Avenue and Neiman Marcus is in talks with creditors about financing for a coming chapter 11 filing.

----

Baidu's AI Chip Unit Kunlunxin Plans Hong Kong Listing

Baidu's AI chip unit Kunlunxin has confidentially filed an application to list on the Hong Kong stock exchange, the latest company to capitalize on the frenzy surrounding artificial intelligence.

----

How Kraft Heinz Lost Its Lock on Mac and Cheese-and American Shoppers

Buzzy upstarts and supermarket knockoffs have eaten into the market share of the leading brand. Years of cost cutting, underinvestment and corporate chaos preceded a planned company split.

----

How Meta's Newest Acquisition Target Got Around Worries Over Its Ties to China

The $2.5 billion deal could herald a new era for China-linked AI companies and U.S. investors.

----

OpenAI Is Paying Employees More Than Any Major Tech Startup in History

The company's stock-based compensation in 2025 reached an average of $1.5 million per employee.

----

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow

Blowout artificial-intelligence spending fills chip maker's coffers, but the Groq deal shows that the company needs to think creatively.

----

Warren Buffett Stayed True to His Ways in His Final Year as Berkshire CEO

Buffett spent the year eschewing expensive deals, selling more stocks than he bought, and adding to the company's cash pile.

----

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround

Elliott Hill's late-December purchase was his first open-market stock buy of 2025.

----

Corcept Therapeutics Shares Drop 50% After FDA Rejects Drug

The FDA cited insufficient evidence of effectiveness for relacorilant in patients with Cushing syndrome and hypertension, sending the stock sharply lower.

----

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval

The FDA approved Vanda's drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.

----

Tech Startups Are Handing Out Free Nicotine Pouches to Boost Productivity

A nicotine replacement for smokers has started popping up in offices in the tech industry, despite health hazards.

----

London Has Best IPO Year Since 2021, PwC Report Says

Eleven initial public offerings raised £1.9 billion in 2025 as a late surge in listings eased fears that the city is stuck in a fundraising drought.

----

Hyatt Hotels Cuts Full-Year Guidance Due to Hurricane Damage in Jamaica

Hyatt now expects adjusted earnings before interest, taxes, depreciation and amortization to be toward the low end of its prior range of $1.09 billion to $1.11 billion.

----

Bankers Are Gearing Up for Another Onslaught of Monster Deals in 2026

Firms are anticipating more spinoffs, crypto M&A and participation from sovereign-wealth funds.

----

Hong Kong IPO Momentum Builds as Six Chinese Firms Seek to Raise Over $2.0 Billion

The companies, spanning from artificial intelligence to chip designers and biopharmaceuticals, aim to raise around US$2.13 billion, according to filings to Hong Kong's exchange operator.

 

(END) Dow Jones Newswires

January 02, 2026 01:00 ET (06:00 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment